Salīdzināt metodes

	MSFC: Multiplās sklerozes funkcionālais kompozīts	EDSS: Kurtzke paplašinātā invaliditātes skalas	MDS-UPDRS
Nozare	Neiroloģija	Neiroloģija	Neiroloģija
Saime	Process / pipeline	Process / pipeline	Process / pipeline
Izcelsmes gads	1999	1983	2008
Autors	Gary Cutter, Richard Rudick, and NMSS Consortium	John F. Kurtzke	Christopher G. Goetz and Movement Disorder Society
Tips	Clinician-administered performance test	Clinician-rated	Clinician-rated
Pirmavots	Cutter, G. R., Baier, M. L., Rudick, R. A., et al. (1999). Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Multiple Sclerosis, 5(4), 244-250.	Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11), 1444-1452.	Goetz, C. G., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23(15), 2129-2170.
Citi nosaukumi	MS Functional Composite	Expanded Disability Status Scale	UPDRS
Saistītās	4	4	5
Kopsavilkums	The Multiple Sclerosis Functional Composite (MSFC) is an objective, performance-based assessment of MS-related disability capturing three key functional domains: lower extremity mobility, upper extremity coordination, and cognitive/processing speed. Developed in 1999 by the National MS Society and adopted widely in clinical trials, the MSFC provides quantifiable endpoints complementing the Expanded Disability Status Scale (EDSS). The three-component design addresses EDSS limitations by including cognition and standardizing measurement via timed tasks.	The EDSS is the most widely used clinical disability rating scale in multiple sclerosis research and practice. Developed by John Kurtzke in 1983, it provides a 0-10 ordinal scale capturing disease severity across eight neurological functional systems and functional status. The EDSS remains the primary endpoint in MS clinical trials and longitudinal cohort studies, with decades of prognostic and comparative data worldwide.	The MDS-UPDRS is the gold-standard clinician-administered rating scale for assessing motor and non-motor manifestations of Parkinson's disease. Developed by the Movement Disorder Society in 2008 to enhance the original UPDRS, it measures disease severity across daily living, motor function, and treatment complications. Used globally in clinical trials, longitudinal cohort studies, and routine neurological practice.